top of page

ASGCT 2026: Skylark Bio is developing a gene therapy for the largest cause of pediatric deafness. They have plans to be in the clinic this summer and early data will come by the end of the year

May 13
1 min read

Updated: May 16

President & CEO Jodi Cook describes how Skylark is targeting the GJB2 gene, and the work that has gone into delivering the gene therapy to the right cells in the inner ear and only those cell.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@Biotech.TV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro_Logo_2023_Primary-4.png

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more

bottom of page